

Meta-analysis of studies comparing adjuvant dexamethasone to glycerol to improve clinical outcome of bacterial meningitis

Siavash Vaziri, Fiezollah Mansouri, Babak Sayad, Keyghobad Ghadiri, Elham Torkashvand, Mansour Rezaei¹, Farid Najafi¹, Mohsen Azizi²

Department of Infectious and Tropical Disease, School of Medicine, ¹Department of Biostatistics and Epidemiology, School of Public Health, Kermanshah University of Medical Sciences, ²Department of Medical Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

Background: Neurological complications are a problematic factor in acute bacterial meningitis; hence, its prevention is the key to ensure the success of meningitis treatment. Glycerol and dexamethasone are both applied in this regard. Oral glycerol is an appropriate alternative instead of intravenous dexamethasone because it does not have problems related to intravenous injection, the high cost, and drug complications. The main objective of this study was to compare the efficacy of adjuvant dexamethasone versus glycerol in order to improve the clinical outcome of bacterial meningitis. **Materials and Methods:** We conducted a search on the available resources including PubMed, Ovid, Elsevier, Cochrane, and another search engines such as Google till 2014. All clinical trials that were performed in the field of comparing the effectiveness of the two drugs and met the inclusion criteria were gathered and after extraction the relative risk (RR) values, the pooled RR was calculated. The main outcome was neurological complications. Meta-analysis of the data was performed in Stata version 11.2 using both fixed and random effect models, weighting each study by inverse of variance. **Results:** In 5 comparative studies (1,340 patients), the rate of neurological complications of glycerol compared to that of dexamethasone was 1.02 [95% confidence interval (CI), 0.98 compared to 1.12]. The rate of neurological complications of dexamethasone compared to dexamethasone + glycerol was 1 (95% CI, 0.97 compared to 1.03), dexamethasone compared to placebo was 0.99 (95% CI, 0.97 compared to 1.03), glycerol compared to glycerol + dexamethasone was 0.98 (95% CI, 0.94 compared to 1.02), and glycerol compared to placebo was 0.97 (95% CI, 0.94 compared to 1.01). In these studies, no difference was reported between dexamethasone and glycerol in terms of reducing neurological complications. **Conclusion:** Although there were some weak evidences for the nonstatistical significant effect of glycerol in the prevention of neurologic complication after meningitis, there was no difference between glycerol and dexamethasone.

Key words: Dexamethasone, glycerol, meningitis, neurological complications

How to cite this article: Vaziri S, Mansouri F, Sayad B, Ghadiri K, Torkashvand E, Rezaei M, Najafi F, Azizi M. Meta-analysis of studies comparing adjuvant dexamethasone to glycerol to improve clinical outcome of bacterial meningitis. J Res Med Sci 2016;21:22.

INTRODUCTION

Bacterial meningitis is a serious infection of the nervous system^[1] and hearing impairment is the most common complication of this disease^[2-4] although other neurological complications such as quadriplegia, spasticity, and mental retardation are also observed after meningitis.^[5-8]

Hearing defects in children have become a growing problem in developing countries, especially in those countries where there are not enough resources for providing rehabilitation facilities and hearing aids. The best solution to prevent bacterial meningitis and its complications is the use of vaccine.^[9,10] The conjugate vaccine against three common causes of meningitis, i.e., *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Neisseria meningitidis* has a significant effect in

Access this article online

Quick Response Code:



Website:

www.jmsjournal.net

DOI:

10.4103/1735-1995.179890

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Address for correspondence: Dr. Farid Najafi, Department of Biostatistics and Epidemiology, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. E-mail: fnajafi@kums.ac.ir

Received: 10-09-2015; **Revised:** 08-12-2015; **Accepted:** 09-02-2016

reducing the incidence of meningitis. However, due to the extremely high demand for the vaccine and the relatively less access to it across the world, its application has not been possible.^[11,12] Furthermore, new antimicrobial factors such as the third-generation cephalosporins have failed in the effective prevention of neurological complications of meningitis.^[13] Hence, doctors believe that these patients may benefit from complementary medicine with antimicrobial treatments.^[14-18] The fact is that the pathophysiologic mechanisms that cause neurological complications of meningitis and hearing defects have not yet been fully recognized^[19-22] but intracerebral edemas with decreased cerebral perfusion, ischemia, and nerve injury have been proposed as the most important factors. In fact, the risk of cerebral edema intensifies when antimicrobial therapy is initiated due to the release of cellular components and toxic agents.^[23] Because the severe inflammatory response in the subarachnoid space can have an important role in the damages caused by meningitis,^[24-26] someone may conclude that steroidal and nonsteroidal anti-inflammatory drugs are effective in inhibiting this inflammation.^[27-29] Hence, dexamethasone has been suggested as an anti-inflammatory drug in preventing neurological complications although the results of various studies have been different in this area.^[28-31] In fact, in different studies the desirable effect of dexamethasone as a complementary therapy, especially in *Haemophilus influenzae* meningitis in children has been proved.^[14-18] Furthermore, because of the increase in intracranial pressure during meningitis, the use of hyperosmolar agents such as glycerol is also strongly recommended.^[31,32] Glycerol has been widely used as an osmotic dehydrating agent and has been applied as a safe drug for children and adults in the treatment of cerebral edema, increased intracranial pressure due to cerebral infarction or intracranial hemorrhage, brain tumors, encephalopathy, Reye's syndrome, and encephalitis. This drug is cheap and readily available and is administered orally. The osmotic property of glycerol decreases the increased intracranial pressure during meningitis.^[32] Considering that various studies have reported different effectiveness for dexamethasone and glycerol in patients with meningitis, we conducted this study to compare the efficacy of adjuvant dexamethasone and/or glycerol in improving the clinical outcome of bacterial meningitis.

MATERIALS AND METHODS

Identification of studies and study selection

In the available published resources PubMed, Ovid, Elsevier, Cochrane, and search engines such as Google, a search was begun with the keywords meningitis, neurological sequelae, dexamethasone, glycerol, and then other keywords such as deafness and hearing loss were added. Meanwhile, journals related to the topic were also studied. After reviewing

the titles and abstracts, 268 articles were obtained. Of these articles, 46 papers that compared the neurological complications of bacterial meningitis prevention by glycerol or dexamethasone were selected. Furthermore, in order to review all studies, references of the mentioned articles were also reviewed. These articles were reviewed by two groups, including the main researcher and colleagues. Finally, clinical trials that compared the effectiveness of oral glycerol to intravenous dexamethasone in preventing neurological complications of bacterial meningitis were included in this study.

Data extraction

The data were extracted based on neurological complications. Neurological complications that were evaluated in our study included the degree of hearing loss, the level of reduction in intracranial pressure, or neurological damage such as paralysis of the limbs and increased plasma osmolality. The studies that only examined the results of the administered dexamethasone and did not compare the two drugs were excluded.^[1,14,16-19,29,33-47] Meanwhile, the studies with objectives other than those of our study were also excluded, for example, if the studies showed the stroke rate reduction,^[48] studies on animals,^[49-52] or the studies that only focused on glycerol and were not comparative.^[31,53-64] In the end, the articles were evaluated by Jadad criteria that are used in assessing the quality of clinical trials and five papers^[11,30,32,65,66] that were based on JADAD criteria and had scores higher than 3 were selected and included in the study [Figure 1]. If there was a serious disagreement between the two groups about some articles in terms of inclusion in the study, an agreement was made in a joint session.




Figure 1: Flow diagram for study selection

Eventually, the two groups separately extracted the required information and the accuracy of the information extraction was also discussed step by step in the joint session and an agreement was made and the final data were collected for the purpose of analysis.

Data synthesis and meta-analysis

To compare neurological complications in both drugs, the relative risk (RR) index was used. After entering the data related to the risk of neurological complications of dexamethasone compared to glycerol and calculation of the standard error of each RR, the studies were combined with both fixed and random effect models so that ultimately the final RR could be calculated. For the meta-analysis, inverse variance method was used by the fixed method and in the random effect model Der Simonian and Laird method was used. For all comparisons, a forest plot diagram was mapped and the results were presented in the form of RR and 95% confidence intervals (CIs). Heterogeneity on RR estimation was tested among different studies by the Q statistic (significant level less than 0.01). Moreover, statistic value I² indicating little heterogeneity between the studies was also calculated. In order to investigate possible publication bias, we uses Egger's and Begg's tests at the 5% significance level. All analyses were done using Stata version 11.2.

RESULTS

Study characteristics

Finally, five studies with a total number of 1,340 patients were included in our study. Because in one article (Peltola, 2007) two ultimate goals of our study were examined separately, i.e., decrease in neurological complications and hearing loss, the results of both the studies were entered separately into our study and in total we meta-analyzed six studies. The results of extracted data from the entered articles are summarized in Table 1.

The oldest study with a sample size of 122 was performed in 1995 and the latest study with a sample size of 383 was conducted in 2009.

In the smallest study, the sample size was 36 and in the Peltola study the sample size was 654, which was the largest study [Table 1].

Main results and findings from meta-analyses

In the comparison of dexamethasone to glycerol in reducing neurological complications of bacterial meningitis among the six studies and based on the fixed effect model, it was shown that no statistically significant difference existed between the two drugs in terms of the incidence rate of

Table 1: Characteristics of the five studies included in the analysis and pooled RR (CI: 95%)

Year	Author	Dexamethasone (M)	GLY orally (M)	DXM plus GLY (M)	Placebo (n)	Dose DXM	Dose GLY	The aim	RR (CI: 95%)
1995	Kilpi	32	30	34	26	1.5 mg/kg/day	4.5 mg/kg/day	Preventing hearing impairment	4.69 (0.30-72.94)
2006	Snakar	12	12	19	12	0.15 mg/kg/qid	1.5 mg/kg/qid	Preventing hearing impairment	2.29 (0.43-12.14)
2007	Peltola (1)	166	166	159	163	0.15 mg/kg/qid	1.5 mg/kg/qid	Neurologic abnormalities	1.48 (0.82-2.67)
2007	Peltola (2)	135	136	132	131	0.15 mg/kg/qid	1.5 Mg/kg/qid	Prevented deafness	1.29 (0.77-2.17)
2008	Singhi	8	9	11	8	0.6 mg/kg/day	6 g/kg/day	Serum osmolality	1.02 (0.97-1.08)
2009	Peltola	191	92	95	95	0.15 mg/kg/qid	1.5 mg/kg/qid	Preventing hearing impairment	1.02 (0.97-1.07)

neurological complications. Hence, the incidence rate of neurological complications of dexamethasone was only 2.1% higher than glycerol, which was certainly not statistically and clinically significant.

(RR: 1.021, 95% CI: 0.98-1.12%) [Figure 2].

It should be noted that *Q* test results showed there was no significant heterogeneity among the different studies ($P=0.36$). The results of test I^2 also confirmed the previous results in that it indicated the variance between the studies to be 0.005.

The results of Egger's test and Begg's test showed that in the current study, there was no publication bias (P values were 0.188 and 0.672, respectively) [Figure 3].

In the comparison of dexamethasone to dexamethasone + glycerol in reducing neurological complications of bacterial meningitis in the six studies and based on the random effect model, it was indicated that no statistically significant

difference existed between the two drugs in terms of the incidence rate of the neurological complications.

(RR: 1, 95% CI: 0.97-1.03%) [Figure 4].

It should be noted that *Q* test results showed that there was no significant heterogeneity among the different studies ($P = 0.648$). The results of test I^2 also confirmed the previous results in that it indicated the variance among studies to be 0.00.

In the comparison of dexamethasone to placebo in reducing neurological complications of bacterial meningitis in the six studies and based on the random effect model, it was indicated that there was no statistically significant difference between the two drugs in terms of the incidence rate of the neurological complications.

(RR: 0.99, 95% CI: 0.97-1.03%) [Figure 5].

It should be noted that *Q* test results showed that there was no significant heterogeneity between different studies ($P=0.477$).




Figure 2: The comparison of dexamethasone with glycerol based on the random effect model




Figure 3: Funnel plot with pseudo 95% confidence limits by event rate




Figure 4: The comparison of dexamethasone with dexamethasone + glycerol based on the random effect model




Figure 5: The comparison of dexamethasone with placebo based on the random effect model

The results of test I^2 also confirmed the previous results in that it indicated that the variance among studies was 0.000.

In the comparison of glycerol to glycerol + dexamethasone in reducing neurological complications of bacterial meningitis in the six studies and based on the random effect model, it was indicated that no statistically significant difference existed between the two drugs in terms of incidence rate of the neurological complications.

(RR: 0.98, 95% CI: 0.94-1.02%) [Figure 6].

It should be noted that Q test results showed that there was no significant heterogeneity between different studies ($P = 0.901$). The results of test I^2 also confirmed the previous results in that it indicated that the variance among studies was 0.000.

In the comparison of glycerol to placebo in reducing neurological complications of bacterial meningitis in the six studies and based on the random effect model, it was indicated that there was no statistically significant difference between the two drugs in terms of incidence rate of the neurological complications.

(RR: 0.97, 95% CI: 0.94-1.01%) [Figure 7].

Despite this result, as it can be seen in Figure 6 it seems that glycerol is more effective than placebo in reducing neurological complications. It should be noted that Q test results showed there was no significant heterogeneity among the different studies ($P = 0.044$). The result of test I^2 also confirmed the previous results in that it indicated that the variance between studies was 0.060.

DISCUSSION

In this study, a comparison between the effectiveness rate of dexamethasone and glycerol in reducing neurological

complications of bacterial meningitis was made, and according to the results there was no statistically significant difference between the two drugs. Although this study did not prove the superiority of glycerol over dexamethasone, given that the figures do not imply its less effectiveness than dexamethasone in the above area, it can be concluded that oral glycerol compared to intravenous dexamethasone can be as successful as dexamethasone in reducing neurological complications of acute bacterial meningitis such as deafness in children. The advantages of glycerol compared to dexamethasone are ease of its administration, more cooperation from and acceptance by the patient, lower complications, and lower cost.

In many clinical trials and meta-analyses, dexamethasone has been compared to placebo and different results have been obtained.^[33-47] In the meta-analysis conducted in 1998, Peter McIntyre *et al.* examined 11 clinical trials and showed that dexamethasone is more effective than placebo in pneumococcal meningitis and is effective in Haemophilus influenza only if it is administered very early (less than 2 h from the onset of disease).^[34]

In another meta-analysis in 2010 by Vandebek, five clinical trials involving a total of 2,029 patients were examined. The results showed that dexamethasone compared to placebo could not reduce neurological complications and mortality.^[47] In another study conducted in 2012 by Kameshwar Prasad, the effect of dexamethasone in reducing neurological complications compared to placebo was only indicated in special circumstances such as pneumococcal meningitis or only in rich countries.^[67] According to the results of the previous studies and the results obtained in our study, the role of dexamethasone in reducing neurological complications of bacterial meningitis is generally unknown but it seems that it can be effective in certain circumstances such as pneumococcal meningitis. In this




Figure 6: The comparison of glycerol with glycerol + dexamethasone based on the random effect model




Figure 7: The comparison of glycerol with placebo based on the random effect model

study, we did not deal with the causes of meningitis separately and only examined all the factors that cause meningitis; so we cannot comment on the effective role of dexamethasone in particular types of meningitis, for example, pneumococcal meningitis.

In the current study, glycerol was compared to placebo and no statistically significant difference was observed between these in reducing neurological complications. Not many studies have compared these two drugs but in two clinical trials on animals, it was indicated that there was no difference between glycerol and placebo in reducing neurological complications. Though in our study there was no significant difference between the two drugs according to RR: 0.97, 95% CI: 0.94-1.01%, it seems that glycerol is more effective than placebo in reducing neurological complications.

In this study, the comparison of glycerol to glycerol + dexamethasone as well as dexamethasone with glycerol + dexamethasone was performed and no significant difference was observed between the two groups. Till date, no clinical trial has been conducted in this field that could be compared to our results.

One of the features of our study was to compare the therapeutic use of dexamethasone and glycerol that has not yet been addressed in meta-analysis studies. We could not examine the causes of meningitis separately because this separation was not addressed in most studies. Another limitation of our study was the lack of access to non-English articles although it did not seem that there was a study in this field in another language.

CONCLUSIONS

Due to the fact that the effect of glycerol is not less effective than dexamethasone in preventing neurological complications of bacterial meningitis, the ease of prescription, lower cost, and lower complications, it is suggested that oral glycerol be used instead of intravenous dexamethasone in reducing neurological complications. However, further studies should be done by focusing on the complications of these two drugs and their effectiveness in reducing neurological complications so that their safe administration is ensured in addition to their effectiveness.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

AUTHORS' CONTRIBUTIONS

SV contributed to the original idea and protocol, conception of the work, conduct of the study, revision of the draft, approval of the final version of the manuscript, and agreed with regard to all aspects of the work. FM contributed to the conception of the work, conduct of the study, revision of the draft, approval of the final version of the manuscript, and agreed with regard to all aspects of the work. BS contributed to the conception of the work, conduct of the study, revision of the draft, approval of the final version of the manuscript, and agreed with regard to all aspects of the work. KGh contributed to the conception of the work, conduct of the study, revision of the draft, approval of the final version of the manuscript, and agreed with regard to all aspects of the work. ET and MA contributed to the conception of the work, conduct of the study, revision of the draft, approval of the final version of the manuscript, and agreed with regard to all aspects of the work. MR contributed in the design of the work, performance of the analysis, revision of the draft, approval of the final version of the manuscript, and agreed with regard to all aspects of the work. FN contributed to the the design of the work, performance of the analysis, writing and editing of this manuscript, revision of the draft, approval of the final version of the manuscript, and agreed with regard to all aspects of the work.

REFERENCES

1. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. *N Engl J Med* 2006;354:44-53.
2. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: A meta-analysis. *Pediatr Infect Dis J* 1993;12:389-94.
3. Kooomen I, Grobbee DE, Roord JJ, Donders R, Jennekens-Schinkel A, van Furth AM. Hearing loss at school age in survivors of bacterial meningitis: Assessment, incidence, and prediction. *Pediatrics* 2003;112:1049-53.
4. Richardson MP, Reid A, Tarlow MJ, Rudd PT. Hearing loss during bacterial meningitis. *Arch Dis Child* 1997;76:134-8.
5. Grimwood K, Anderson P, Anderson V, Tan L, Nolan T. Twelve year outcomes following bacterial meningitis: Further evidence for persisting effects. *Arch Dis Child* 2000;83:111-6.
6. Singhi P, Bansal A, Geeta P, Singhi S. Predictors of long term neurological outcome in bacterial meningitis. *Indian J Pediatr* 2007;74:369-74.
7. George CN, Letha S, Bai SS. A clinical study of chronic morbidity in children following pyogenic meningitis. *Indian Pediatr* 2002;39:663-7.
8. Wandt F, Kiagi G, Duke T. Long-term outcome for children with bacterial meningitis in rural Papua New Guinea. *J Trop Pediatr* 2005;51:51-3.
9. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev* 2000;13:302-17.
10. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, *et al.* Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser

- Permanente Vaccine Study Center Group. *Pediatr Infect Dis J* 2000;19:187-95.
11. Singhi S, Järvinen A, Peltola H. Increase in serum osmolality is possible mechanism for the beneficial effects of glycerol in childhood bacterial meningitis. *Pediatr Infect Dis J* 2008;27:892-6.
 12. Sierra-Fernandez H, Schultz-Faingezicht M, SoleyGutierrez C, Guevara-Jime Sn, Arguedas-Mohs A. Estado actual de la yacunuconjugadacotra *Streptococcus pneumoniae*. *Acta Med Croatica* 2006;48:66-71.
 13. Peltola H, Anttila M, Renkonen OV. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group. *Lancet* 1989;333:1281-7.
 14. Lebel MH, Freij BJ, Syrogiannopoulos GA, Chrane DF, Hoyt MJ, Stewart SM, *et al.* Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. *N Engl J Med* 1988;319:964-71.
 15. Mustafa MM, Ramilo O, Mertsola J, Risser RC, Beutler B, Hansen EJ, *et al.* Modulation of inflammation and cachectin activity in relation to treatment of experimental *Haemophilus influenzae* type b meningitis. *J Infect Dis* 1989;160:818-25.
 16. Odio CM, Faingezicht I, Paris M, Nassar M, Baltodano A, Rogers J, *et al.* The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. *N Engl J Med* 1991;324:1525-31.
 17. Schaad UB, Lips U, Gnehm HE, Blumberg A, Heinzer I, Wedgwood J. Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group. *Lancet* 1993;342:457-61.
 18. Sáez-Llorens X, McCracken GH Jr. Antimicrobial and anti-inflammatory treatment of bacterial meningitis. *Infect Dis Clin North Am* 1999;13:619-36, vii.
 19. Leib SL, Täuber MG. Pathogenesis of bacterial meningitis. *Infect Dis Clin North Am* 1999;13:527-48, v-vi.
 20. Nathan BR, Scheld WM. New advances in the pathogenesis and pathophysiology of bacterial meningitis. *Curr Infect Dis Rep* 2000;2:332-6.
 21. Sáez-Llorens X, McCracken GH Jr. Bacterial meningitis in children. *Lancet* 2003;361:2139-48.
 22. Ashwal S, Stringer W, Tomasi L, Schnelder S, Thompson J, Perkin R. Cerebral blood flow and carbon dioxide reactivity in children with bacterial meningitis. *J Pediatr* 1990;117:523-30.
 23. Hurley JC. Antibiotic-induced release of endotoxin: A reappraisal. *Clin Infect Dis* 1992;15:840-54.
 24. Sáez-Llorens X, Ramilo O, Mustafa MM, Mertsold J, McCracken GH Jr. Molecular pathophysiology of bacterial meningitis: Current concepts and therapeutic implications. *J Pediatr* 1990;116:671-84.
 25. Tunkel AR, Wispelwey B, Scheld WM. Bacterial meningitis: Recent advances in pathophysiology and treatment. *Ann Intern Med* 1990;112:610-23.
 26. Quagliariello V, Scheld WM. Bacterial meningitis: Pathogenesis, pathophysiology, and progress. *N Engl J Med* 1992;327:864-72.
 27. Täuber MG, Khayam-Bashi H, Sande MA. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis. *J Infect Dis* 1985;151:528-34.
 28. Mustafa MM, Ramilo O, Olsen KD, Franklin PS, Hansen EJ, Beutler B, *et al.* Tumor necrosis factor in mediating experimental *Haemophilus influenzae* type B meningitis. *J Clin Invest* 1989;84:1253-9.
 29. Sáez-Llorens X, Jafari H, Severien C, Parras F, Olsen KD, Hansen EJ, *et al.* Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental *Haemophilus meningitis*. *J Clin Invest* 1991;88:2003-11.
 30. Peltola H, Roine I, Fernández J, Zavala I, Ayala SG, Mata AG, *et al.* Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: A prospective, randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 2007;45:1277-86.
 31. Cantore G, Guidetti B, Virno M. Oral glycerol for the reduction of intracranial pressure. *J Neurosurg* 1964;21:278-83.
 32. Kilpi T, Peltola H, Jauhiainen T, Kallio MJ. Oral glycerol versus intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. The Finnish Study Group. *Pediatr Infect Dis J* 1995;14:270-8.
 33. Girgis NI, Farid Z, Mikhail IA, Farrag I, Sultan Y, Kilpatrick ME. Dexamethasone treatment for bacterial meningitis in children and adults. *Pediatr Infect Dis J* 1989;8:848-51.
 34. McIntyre PB, Berkey CS, King SM, Schaad UB, Kilpi T, Kanra GY, *et al.* Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. *JAMA* 1997;278:925-31.
 35. Group CS. The effectiveness of hydrocortisone in the management of severe infections. *JAMA* 1963;183:462-5.
 36. DeLemos RA, Haggerty RJ. Corticosteroids as an adjunct to treatment in bacterial meningitis. A controlled clinical trial. *Pediatrics* 1969;44:30-4.
 37. Lebel MH, Hoyt MJ, Waagner DC, Rollins NK, Finitzo T, McCracken GH Jr. Magnetic resonance imaging and dexamethasone therapy for bacterial meningitis. *Am J Dis Child* 1989;143:301-6.
 38. Nguyen TH, Tran TH, Thwaites G, Ly VC, Dinh XS, Ho Dang TN, *et al.* Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. *N Engl J Med* 2007;357:2431-40.
 39. Scarborough M, Gordon SB, Whitty CJ, French N, Njalale Y, Chitani A, *et al.* Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. *N Engl J Med* 2007;357:2441-50.
 40. Vardakas KZ, Matthaïou DK, Falagas ME. Adjunctive dexamethasone therapy for bacterial meningitis in adults: A meta-analysis of randomized controlled trials. *Eur J Neurol* 2009;16:662-73.
 41. Assiri AM, Alasmari FA, Zimmerman VA, Baddour LM, Erwin PJ, Tleyjeh IM. Corticosteroid administration and outcome of adolescents and adults with acute bacterial meningitis: A meta-analysis. *Mayo Clin Proc* 2009;84:403-9.
 42. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev* 2007;CD004405.
 43. van de Beek D, Weisfelt M, de Gans J, Tunkel AR, Wijdicks EF. Drug insight: Adjunctive therapies in adults with bacterial meningitis. *Nat Clin Pract Neurol* 2006;2:504-16.
 44. Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev* 2010;CD004405.
 45. Havens PL, Wendelberger KJ, Hoffman GM, Lee MB, Chusid MJ. Corticosteroids as adjunctive therapy in bacterial meningitis: A meta-analysis of clinical trials. *Am J Dis Chil* 1989;143:1051-5.
 46. van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: A systematic review. *Lancet Infect Dis* 2004;4:139-43.
 47. van de Beek D, Farrar JJ, de Gans J, Mai NT, Molyneux EM, Peltola H, *et al.* Adjunctive dexamethasone in bacterial meningitis: A meta-analysis of individual patient data. *Lancet Neurol* 2010;9:254-63.
 48. Gilsanz V, Rebollar JL, Buencuerpo J, Chantres MT. Controlled trial of glycerol versus dexamethasone in the treatment of cerebral edema in acute cerebral infarction. *Lancet* 1975;1:1049-51.
 49. Chan PH, Pollack E, Fishman RA. Differential effects of hypertonic mannitol and glycerol on rat brain metabolism and amino acids. *Brain Res* 1981;225:143-53.

50. Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. *Am J Physiol* 1978;235:H299-307.
51. Schmidt H, Stuertz K, Chen V, Stringaris A, Brück W, Nau R. Glycerol does not reduce neuronal damage in experimental *Streptococcus pneumoniae* meningitis in rabbits. *Inflammopharmacology* 1998;6:19-26.
52. Blaser C, Klein M, Grandgirard D, Wittwer M, Peltola H, Weigand M, *et al.* Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis. *BMC Infect Dis* 2010;10:84.
53. Yu YL, Kumana CR, Lauder IJ, Cheung YK, Chan FL, Kou M, *et al.* Treatment of acute cortical infarct with intravenous glycerol. A double-blind, placebo-controlled randomized trial. *Stroke* 1993;24:1119-24.
54. Meyer JS, Charney JZ, Rivera VM, Mathew NT. Treatment with glycerol of cerebral oedema due to acute cerebral infarction. *Lancet* 1971;2:993-7.
55. Tourtellotte WW, Reinglass JL, Newkirk TA. Cerebral dehydration action of glycerol. I. Historical aspects with emphasis on the toxicity and intravenous administration. *Clin Pharmacol Ther* 1972;13:159-71.
56. Rottenberg DA, Hurwitz BJ, Posner JB. The effect of oral glycerol on intraventricular pressure in man. *Neurology* 1977;27:600-8.
57. MacDonald JT, Uden DL. Intravenous glycerol and mannitol therapy in children with intracranial hypertension. *Neurology* 1982;32:437-440.
58. Node Y, Nakazawa S. Clinical study of mannitol and glycerol on raised intracranial pressure and on their rebound phenomenon. *Adv Neurol* 1989;52:359-63.
59. Cantore GP, Guidetti B, Pecori-Giraldi J, Virno M. Intravenous glycerol in the treatment of intracranial hypertension. (Preliminary note). *Polislinico Prat* 1966;73:553-61.
60. Mathew NT, Rivera VM, Meyer JS, Charney JZ, Hartmann A. Double-blind evaluation of glycerol therapy in acute cerebral infarction. *Lancet* 1972;2:1327-9.
61. Bayer A, Pathy MJ, Newcombe R. Double-blind randomised trial of intravenous glycerol in acute stroke. *Lancet* 1987;329:405-8.
62. Dodson RF, Tagashira Y, Wai-Fong Chu L. The effects of glycerol on cerebral ultrastructure following experimentally induced cerebral ischemia. *J Neurol Sci* 1975;26:235-43.
63. Kashiwagi F, Katayama Y, Shimizu J, Suzuki S, Iida S, Terashi A. Effect of timing and dose of the hyperosmotic agent glycerol on experimental ischemic brain edema and metabolites. *Adv Neurol* 1990;52:541.
64. Ajdukiewicz KM, Cartwright KE, Scarborough M, Mwambene JB, Goodson P, Molyneux ME, *et al.* Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: A double-blind, randomised controlled trial. *Lancet Infect Dis* 2011;11:293-300.
65. Sankar J, Singhi P, Bansal A, Ray P, Singhi S. Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. *Indian Pediatr* 2007;44:649-56.
66. Peltola H, Roine I, Fernández J, González Mata A, Zavala I, Gonzalez Ayala S, *et al.* Hearing impairment in childhood bacterial meningitis is little relieved by dexamethasone or glycerol. *Pediatrics* 2010;125:e1-8.
67. Prasad K, Rai NK, Kumar A. Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults. *Curr Infect Dis Rep* 2012;14:445-53.